Teladoc Inc (NYSE:TDOC) has earned an average recommendation of “Buy” from the twenty-three research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $69.78.

A number of research analysts have issued reports on TDOC shares. Canaccord Genuity raised their price target on shares of Teladoc from $70.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup raised their target price on shares of Teladoc to $80.00 and gave the stock a “buy” rating in a report on Thursday, July 19th. Piper Jaffray Companies raised their target price on shares of Teladoc to $77.00 and gave the stock an “overweight” rating in a report on Thursday, August 2nd. Chardan Capital raised their target price on shares of Teladoc from $73.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Finally, Berenberg Bank started coverage on shares of Teladoc in a report on Monday, July 9th. They set a “buy” rating and a $72.00 target price for the company.

Shares of NYSE TDOC traded up $2.70 during midday trading on Friday, reaching $78.10. The company had a trading volume of 1,429,622 shares, compared to its average volume of 1,055,188. The stock has a market cap of $5.43 billion, a P/E ratio of -47.33 and a beta of 0.58. Teladoc has a 1 year low of $27.30 and a 1 year high of $79.64. The company has a current ratio of 3.14, a quick ratio of 3.14 and a debt-to-equity ratio of 0.58.

Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.01. The business had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $91.56 million. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The business’s quarterly revenue was up 112.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.28) earnings per share. sell-side analysts forecast that Teladoc will post -1.51 earnings per share for the current year.

In related news, SVP Andrew Turitz sold 13,821 shares of the firm’s stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $59.43, for a total transaction of $821,382.03. Following the sale, the senior vice president now owns 9,378 shares in the company, valued at $557,334.54. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Adam C. Vandervoort sold 24,250 shares of the firm’s stock in a transaction on Monday, July 9th. The shares were sold at an average price of $64.28, for a total transaction of $1,558,790.00. Following the sale, the insider now owns 12,272 shares in the company, valued at approximately $788,844.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 268,781 shares of company stock valued at $18,083,387. 3.95% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Teladoc by 9.0% during the second quarter. BlackRock Inc. now owns 5,318,850 shares of the health services provider’s stock valued at $308,759,000 after buying an additional 437,136 shares during the period. JPMorgan Chase & Co. grew its position in Teladoc by 1.4% during the first quarter. JPMorgan Chase & Co. now owns 4,678,836 shares of the health services provider’s stock valued at $188,559,000 after buying an additional 65,383 shares during the period. Bamco Inc. NY grew its position in Teladoc by 0.3% during the first quarter. Bamco Inc. NY now owns 1,938,000 shares of the health services provider’s stock valued at $78,101,000 after buying an additional 6,500 shares during the period. Bank of America Corp DE grew its position in Teladoc by 82.8% during the second quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock valued at $109,318,000 after buying an additional 853,076 shares during the period. Finally, Zevenbergen Capital Investments LLC grew its position in Teladoc by 3.9% during the second quarter. Zevenbergen Capital Investments LLC now owns 1,629,170 shares of the health services provider’s stock valued at $94,574,000 after buying an additional 61,325 shares during the period.

About Teladoc

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: How to Invest in Growth Stocks

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.